TY - JOUR AU - Bradford, P. T. AU - Devesa, S. S. AU - Anderson, W. F. PY - 2009 DA - 2009// TI - Cutaneous lymphoma incidence patters in the United States: a population based study of 3884 cases JO - Blood VL - 113 ID - Bradford2009 ER - TY - JOUR AU - Olsen, E. AU - Vonderheid, E. AU - Pimpinelli, N. PY - 2007 DA - 2007// TI - Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization for research and treatment of cancer (EORTC) JO - Blood VL - 110 ID - Olsen2007 ER - TY - JOUR AU - Agar, N. S. AU - Wedgeworth, E. AU - Crichton, S. PY - 2010 DA - 2010// TI - Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised international society for cutaneous lymphomas/European organization for research and treatment of cancer staging proposal JO - J Clin Oncol VL - 28 ID - Agar2010 ER - TY - JOUR AU - Kim, Y. H. AU - Liu, H. L. AU - Mraz-Gernhard, S. PY - 1996 DA - 1996// TI - Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression JO - Arch Dermatol VL - 139 ID - Kim1996 ER - TY - JOUR AU - Horwitz, S. M. AU - Olsen, E. A. AU - Duvic, M. PY - 2008 DA - 2008// TI - Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach JO - J Natl Compr Canc Netw VL - 6 ID - Horwitz2008 ER - TY - JOUR AU - Trautinger, F. AU - Knobler, R. AU - Willemze, R. PY - 2006 DA - 2006// TI - EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome JO - Eur J Cancer VL - 42 ID - Trautinger2006 ER - TY - JOUR AU - Prince, H. M. AU - Whittaker, S. AU - Hoppe, R. T. PY - 2009 DA - 2009// TI - How I treat mycosis fungoides and Sezary syndrome JO - Blood VL - 114 ID - Prince2009 ER - TY - JOUR AU - Arulogan, S. O. AU - Prince, H. M. AU - Ng, J. PY - 2008 DA - 2008// TI - Long-term outcomes of patients with advanced stage cutaneous T-cell lymphoma and large cell transformation JO - Blood VL - 112 ID - Arulogan2008 ER - TY - JOUR AU - Olsen, E. A. AU - Whittaker, S. AU - Kim, Y. H. PY - 2011 DA - 2011// TI - Clinical end points and response criteria in mycosis fungoides and sezary syndrome: a consensus statement of the International Society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European organization for research and treatment of cancer JO - J Clin Oncol VL - 18 ID - Olsen2011 ER - TY - JOUR AU - Piekarz, R. AU - Bates, S. PY - 2009 DA - 2009// TI - Epigenetic modifiers: basic understanding and clinical development JO - Clin Cancer Res VL - 15 ID - Piekarz2009 ER - TY - JOUR AU - Johnstone, R. W. AU - Licht, J. D. PY - 2003 DA - 2003// TI - Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? JO - Cancer Cell VL - 4 ID - Johnstone2003 ER - TY - JOUR AU - Sandor, V. AU - Senderowicz, A. AU - Mertins, S. PY - 2000 DA - 2000// TI - P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 JO - Br J Cancer VL - 83 ID - Sandor2000 ER - TY - JOUR AU - Sambucetti, L. C. AU - Fischer, D. D. AU - Zabludoff, S. PY - 1999 DA - 1999// TI - Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects JO - J Biol Chem VL - 274 ID - Sambucetti1999 ER - TY - JOUR AU - Classon, M. AU - Harlow, E. PY - 2002 DA - 2002// TI - The retinoblastoma tumour suppressor in development and cancer JO - Nat Rev Cancer VL - 2 ID - Classon2002 ER - TY - JOUR AU - Gui, C. Y. AU - Ngo, L. AU - Xu, W. S. PY - 2004 DA - 2004// TI - Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 JO - Proc Natl Acad Sci USA VL - 101 ID - Gui2004 ER - TY - JOUR AU - Richon, V. M. AU - Sandhoff, T. W. AU - Rifkind, R. A. PY - 2000 DA - 2000// TI - Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation JO - Proc Natl Acad Sci USA VL - 97 ID - Richon2000 ER - TY - JOUR AU - Peart, M. J. AU - Tainton, K. M. AU - Ruefli, A. A. PY - 2003 DA - 2003// TI - Novel mechanisms of apoptosis induced by histone deacetylase inhibitors JO - Cancer Res VL - 63 ID - Peart2003 ER - TY - JOUR AU - Ruefli, A. A. AU - Ausserlechner, M. J. AU - Bernhard, D. PY - 2001 DA - 2001// TI - The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species JO - Proc Natl Acad Sci USA VL - 98 ID - Ruefli2001 ER - TY - JOUR AU - Jones, L. K. AU - Saha, V. PY - 2002 DA - 2002// TI - Chromatin modification, leukaemia and implications for therapy JO - Br J Haematol VL - 118 ID - Jones2002 ER - TY - JOUR AU - Nebbioso, A. AU - Clarke, N. AU - Voltz, E. PY - 2005 DA - 2005// TI - Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells JO - Nat Med VL - 11 ID - Nebbioso2005 ER - TY - JOUR AU - Guo, F. AU - Sigua, C. AU - Tao, J. PY - 2004 DA - 2004// TI - Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells JO - Cancer Res VL - 64 ID - Guo2004 ER - TY - JOUR AU - Butler, L. M. AU - Zhou, X. AU - Xu, W. S. PY - 2002 DA - 2002// TI - The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin JO - Proc Natl Acad Sci USA VL - 99 ID - Butler2002 ER - TY - JOUR AU - Wolf, D. AU - Rodova, M. AU - Miska, E. A. PY - 2002 DA - 2002// TI - Acetylation of [beta]-catenin by CREB-binding protein (CBP) JO - J Biol Chem VL - 277 ID - Wolf2002 ER - TY - JOUR AU - Bannister, A. J. AU - Miska, E. A. AU - Gorlich, D. PY - 2000 DA - 2000// TI - Acetylation of importin-a nuclear import factors by CBP/p300 JO - Curr Biol VL - 10 ID - Bannister2000 ER - TY - JOUR AU - Cohen, H. Y. AU - Lavu, S. AU - Bitterman, K. J. PY - 2004 DA - 2004// TI - Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis JO - Mol Cell VL - 13 ID - Cohen2004 ER - TY - JOUR AU - Kim, M. S. AU - Kwon, H. J. AU - Lee, Y. M. PY - 2001 DA - 2001// TI - Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes JO - Nat Med VL - 7 ID - Kim2001 ER - TY - JOUR AU - Mie Lee, Y. AU - Kim, S. H. AU - Kim, H. S. PY - 2003 DA - 2003// TI - Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1a activity JO - Biochem Biophys Res Commun VL - 300 ID - Mie Lee2003 ER - TY - JOUR AU - Marquard, L. AU - Gjerdrum, L. M. AU - Christensen, I. J. PY - 2008 DA - 2008// TI - Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma JO - Histopathology VL - 53 ID - Marquard2008 ER - TY - JOUR AU - Mann, B. S. AU - Johnson, J. R. AU - Cohen, M. H. PY - 2007 DA - 2007// TI - FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma JO - Oncologist VL - 12 ID - Mann2007 ER - TY - STD TI - [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189629.htm] UR - http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189629.htm ID - ref30 ER - TY - JOUR AU - Zhang, C. AU - Richon, V. AU - Ni, X. PY - 2005 DA - 2005// TI - Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells. Relevance to mechanism of therapeutic action JO - J Invest Dermatol VL - 125 ID - Zhang2005 ER - TY - JOUR AU - Kelly, W. K. AU - Richon, V. M. AU - O’Connor, O. A. PY - 2003 DA - 2003// TI - Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously JO - Clin Cancer Res VL - 9 ID - Kelly2003 ER - TY - JOUR AU - O’Connor, O. A. AU - Heaney, M. L. AU - Schwartz, L. PY - 2006 DA - 2006// TI - Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies JO - J Clin Oncol VL - 24 ID - O’Connor2006 ER - TY - JOUR AU - Duvic, M. AU - Talpur, R. AU - Ni, X. PY - 2007 DA - 2007// TI - Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) JO - Blood VL - 109 ID - Duvic2007 ER - TY - JOUR AU - Olsen, E. A. AU - Kim, Y. H. AU - Kuzel, T. M. PY - 2007 DA - 2007// TI - Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma JO - J Clin Oncol VL - 25 ID - Olsen2007 ER - TY - CHAP AU - Duvic, M. AU - Kim, Y. H. AU - Kuzel, T. M. PY - 2009 DA - 2009// TI - The systemic effects of vorinostat in Patients with cutaneous T-cell lymphoma (CTCL): Post-Hoc analysis in patients with high blood tumor burden BT - Blood ID - Duvic2009 ER - TY - JOUR AU - Gardner, J. M. AU - Introcaso, C. E. AU - Nasta, S. D. PY - 2009 DA - 2009// TI - A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome JO - J Am cad Dermatol VL - 61 ID - Gardner2009 ER - TY - JOUR AU - Piekarz, R. L. AU - Robey, R. W. AU - Zhan, Z. PY - 2004 DA - 2004// TI - T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance JO - Blood VL - 103 ID - Piekarz2004 ER - TY - JOUR AU - Piekarz, R. L. AU - Robey, R. W. AU - Sandor, V. PY - 2001 DA - 2001// TI - Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report JO - Blood VL - 98 ID - Piekarz2001 ER - TY - JOUR AU - Piekarz, R. AU - Frye, R. AU - Turner, M. PY - 2009 DA - 2009// TI - Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma JO - J Clin Oncol VL - 27 ID - Piekarz2009 ER - TY - JOUR AU - Whittaker, S. AU - Demierre, M. F. AU - Kim, E. J. PY - 2010 DA - 2010// TI - Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma JO - J Clin Oncol VL - 28 ID - Whittaker2010 ER - TY - JOUR AU - Therasse, P. AU - Arbuck, S. G. AU - Eisenhauer, E. A. PY - 2000 DA - 2000// TI - New guidelines to evaluate the response to treatment in solid tumors: European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of canada JO - J Natl Cancer Inst VL - 92 ID - Therasse2000 ER - TY - JOUR AU - Cheson, B. D. AU - Pfistner, B. AU - Juweid, M. E. PY - 2007 DA - 2007// TI - Revised response criteria for malignant lymphoma JO - J Clin Oncol VL - 25 ID - Cheson2007 ER - TY - JOUR AU - Stevens, S. R. AU - Ke, M. S. AU - Parry, E. J. PY - 2002 DA - 2002// TI - Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT) JO - Arch Dermatol VL - 138 ID - Stevens2002 ER - TY - JOUR AU - Heald, P. PY - 2001 DA - 2001// TI - Clinical trials and efficacy assessment in the therapy of cutaneous T-cell lymphoma JO - Ann NY cad Sci VL - 941 ID - Heald2001 ER - TY - JOUR AU - Olsen, E. AU - Duvic, M. AU - Frankel, A. PY - 2001 DA - 2001// TI - Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma JO - J Clin Oncol VL - 19 ID - Olsen2001 ER - TY - JOUR AU - Edelson, R. AU - Berger, C. AU - Gasparro, F. PY - 1987 DA - 1987// TI - Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherpy: Preliminary result JO - N Engl J Med VL - 316 ID - Edelson1987 ER - TY - JOUR AU - Steele, N. L. AU - Plumb, J. A. AU - Vidal, L. PY - 2008 DA - 2008// TI - A phase I pharmacokinetic and pharmacodynamics study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors JO - Clin Cancer Res VL - 14 ID - Steele2008 ER - TY - JOUR AU - Piekarz, R. AU - Frye, R. AU - Wright, J. PY - 2006 DA - 2006// TI - Cardiac studies in patients with depsipeptide, FK28, in a phase II trial for T-cell lymphoma JO - Clin Cancer Res VL - 12 ID - Piekarz2006 ER - TY - JOUR AU - Gimsing, P. AU - Hansen, M. AU - Knudsen, L. M. PY - 2008 DA - 2008// TI - A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia JO - Eur J Haematol VL - 81 ID - Gimsing2008 ER - TY - JOUR AU - Steele, N. L. AU - Plumb, J. A. AU - Vidal, L. PY - 2011 DA - 2011// TI - Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101) JO - Cancer Chemother Pharmacol VL - 67 ID - Steele2011 ER - TY - JOUR AU - Kelly, W. K. AU - DeBono, J. AU - Blumenschein, G. PY - 2009 DA - 2009// TI - Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors JO - J Clin Oncol (Meeting Abstracts) VL - 27 ID - Kelly2009 ER - TY - CHAP AU - Pohlman, B. AU - Advani, R. H. AU - Duvic, M. PY - 2009 DA - 2009// TI - Final results of a phase II trial of Belinostat (PXD-101) in patients with recurrent ore refractory peripheral or cutaneous T-cell lymphoma BT - Blood ID - Pohlman2009 ER - TY - JOUR AU - Ellis, L. AU - Pan, Y. AU - Smyth, G. K. PY - 2008 DA - 2008// TI - Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma JO - Clin Cancer Res VL - 14 ID - Ellis2008 ER - TY - CHAP AU - Duvic, M. AU - Becker, J. C. AU - Dalle, S. PY - 2008 DA - 2008// TI - Phase II trial of Oral Panobinostat in patients with refractory Cutaneous T-cell Lymphoma BT - Blood ID - Duvic2008 ER - TY - JOUR AU - Mandawat, A. AU - Fiskus, W. AU - Buckley, K. M. PY - 2010 DA - 2010// TI - Pan-histone deacetylase (HDAC) inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic anti-myeloid activity in combination with CXCR4 antagonists JO - Blood VL - 116 ID - Mandawat2010 ER - TY - CHAP AU - Zhang, C. AU - Zhang, X. AU - Li, B. PY - 2009 DA - 2009// TI - Molecular and biological characteristics of acquired vorinostat-resistant cutaneous T-cell lymphoma cells BT - Blood ID - Zhang2009 ER - TY - JOUR AU - Fotheringham, S. AU - Epping, M. T. AU - Stimson, L. PY - 2009 DA - 2009// TI - Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis JO - Cancer Cell VL - 15 ID - Fotheringham2009 ER - TY - JOUR AU - Khan, O. AU - Fotheringham, S. AU - Wood, V. PY - 2010 DA - 2010// TI - HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy JO - Proc Natl Acad Sci U S A VL - 107 ID - Khan2010 ER - TY - JOUR AU - O’Connor, O. A. AU - Pro, B. AU - Pinter-Brown, L. L. PY - 2009 DA - 2009// TI - Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) JO - J Clin Oncol VL - 27 ID - O’Connor2009 ER - TY - JOUR AU - Sirotnak, F. M. AU - DeGraw, J. I. AU - Moccio, D. M. PY - 1984 DA - 1984// TI - New folate analogs of the 10-deaza-aminopterin series: Basis for structural design and biochemical and pharmacologic properties JO - Cancer Chemother Pharmacol VL - 12 ID - Sirotnak1984 ER - TY - JOUR AU - Wang, E. S. AU - O’Connor, O. A. AU - She, Y. PY - 2003 DA - 2003// TI - Activity of a novel antifolate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression JO - Leuk Lymphoma VL - 44 ID - Wang2003 ER - TY - JOUR AU - Izbicka, E. AU - Diaz, A. AU - Saunders, M. PY - 2009 DA - 2009// TI - Distince mechansistic activity profile of pralatrexate in comparison to other antifolates in vitro and in vivo molds of human cancers JO - Cancer Chemother Pharmacol VL - 64 ID - Izbicka2009 ER - TY - CHAP AU - Foss, F. M. AU - Horwitz, S. M. AU - Brown, L. P. PY - 2010 DA - 2010// TI - Pralatrexate is an effective treatment for heavily pretreated patients with relapsed/refractory transformed mycosis fungoides (tMF) BT - Blood ID - Foss2010 ER - TY - CHAP AU - Horwitz, S. M. AU - Kim, Y. H. AU - Foss, F. M. PY - 2010 DA - 2010// TI - Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL): Final results of a multicenter dose-finding study BT - Blood ID - Horwitz2010 ER - TY - JOUR AU - Enrica, M. a. r. c. h. i. AU - Luca, P. a. o. l. u. z. z. i. AU - Luigi, S. c. o. t. t. o. PY - 2010 DA - 2010// TI - Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies JO - Clin Cancer Res VL - 16 ID - Enrica2010 ER - TY - JOUR AU - Ri, M. AU - Iida, S. AU - Ishida, T. PY - 2009 DA - 2009// TI - Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1 JO - Cancer Sci VL - 100 ID - Ri2009 ER - TY - JOUR AU - Richardson, P. G. AU - Sonneveld, P. AU - Schuster, M. W. PY - 2005 DA - 2005// TI - Bortezomib or high-dose dexamethasone for relapsed multiple myeloma JO - New Engl J Med VL - 352 ID - Richardson2005 ER - TY - JOUR AU - O’Connor, O. A. AU - Wright, J. AU - Moskowitz, C. PY - 2005 DA - 2005// TI - Phase II clinical experience with the novel proteasome inhibitor bortezomib inpatients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma JO - J Clin Oncol VL - 23 ID - O’Connor2005 ER - TY - JOUR AU - Adams, J. PY - 2004 DA - 2004// TI - The proteasome: a suitable antineoplastic target JO - Nat Rev Cancer VL - 4 ID - Adams2004 ER - TY - JOUR AU - An, B. AU - Goldfarb, R. H. AU - Siman, R. PY - 1998 DA - 1998// TI - Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts JO - Cell Death Differ VL - 5 ID - An1998 ER - TY - JOUR AU - Orlowski, R. Z. AU - Eswara, J. R. AU - Lafond-Walker, A. PY - 1998 DA - 1998// TI - Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor JO - Cancer Res VL - 58 ID - Orlowski1998 ER - TY - JOUR AU - Masdehors, P. AU - Merle-Béral, H. AU - Maloum, K. PY - 2000 DA - 2000// TI - Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes JO - Blood VL - 96 ID - Masdehors2000 ER - TY - JOUR AU - LeBlanc, R. AU - Catley, L. P. AU - Hideshima, T. PY - 2002 DA - 2002// TI - Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model JO - Cancer Res VL - 62 ID - LeBlanc2002 ER - TY - JOUR AU - Hideshima, T. AU - Richardson, P. AU - Chauhan, D. PY - 2001 DA - 2001// TI - The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells JO - Cancer Res VL - 61 ID - Hideshima2001 ER - TY - JOUR AU - Zinzani, P. L. AU - Musuraca, G. AU - Tani, M. PY - 2007 DA - 2007// TI - Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma JO - J Clin Oncol VL - 25 ID - Zinzani2007 ER - TY - JOUR AU - Lee, J. AU - Suh, C. AU - Kang, H. J. PY - 2008 DA - 2008// TI - Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma JO - Ann Oncol VL - 19 ID - Lee2008 ER - TY - JOUR AU - Susan, D. D. AU - Christopher, J. K. AU - Monette, A. PY - 2007 DA - 2007// TI - Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome JO - Cancer Res VL - 67 ID - Susan2007 ER - TY - JOUR AU - Vij, R. AU - Wang, M. AU - Orlowski, R. PY - 2009 DA - 2009// TI - PX-171-004, a multicenter phase II study of carfilzomib in patients with relapsed myeloma: An efficacy update JO - J Clin Oncol VL - 27 ID - Vij2009 ER - TY - CHAP AU - Wang, L. AU - Siegel, D. AU - Kaufman, J. L. PY - 2009 DA - 2009// TI - Updated results of bortezomib-naïve patients in PX-171-004, an ongoing open label, phase II study of single agent carfilzomib in patients with relapsed or refractory MM BT - Blood ID - Wang2009 ER - TY - JOUR AU - Duvic, M. AU - Forero-Torres, A. AU - Foss, F. PY - 2009 DA - 2009// TI - Long-term treatment of CTCL with oral PNP inhibitor, forodesine JO - J Clin Oncol VL - 27 ID - Duvic2009 ER - TY - JOUR AU - Ginaldi, L. AU - Martinis, M. AU - Matutes, E. PY - 1998 DA - 1998// TI - Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H JO - Leuk Res VL - 22 ID - Ginaldi1998 ER - TY - JOUR AU - Capalbo, S. AU - Delia, M. AU - Dargenio, M. PY - 2003 DA - 2003// TI - Mycosis fungoides/Sezary syndrome: a report of three cases treated with Campath-IH as salvage treatment JO - Medical Oncology VL - 20 ID - Capalbo2003 ER - TY - JOUR AU - Kennedy, G. A. AU - Seymour, J. F. AU - Wolf, M. PY - 2003 DA - 2003// TI - Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab JO - Eur J Haematol VL - 71 ID - Kennedy2003 ER - TY - JOUR AU - Lundin, J. AU - Hagberg, H. AU - Repp, R. PY - 2003 DA - 2003// TI - Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome JO - Blood VL - 101 ID - Lundin2003 ER - TY - JOUR AU - Gautschi, O. AU - Blumenthal, N. AU - Streit, M. PY - 2004 DA - 2004// TI - Successful treatment of chemotherapy refractory Sezary syndrome with alemtuzumab (Campath-1H) JO - Eur J Haematol VL - 72 ID - Gautschi2004 ER - TY - JOUR AU - Querfeld, C. AU - Mehta, N. AU - Rosen, T. PY - 2009 DA - 2009// TI - Alemtuzumb for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center JO - Leuk Lymphoma VL - 50 ID - Querfeld2009 ER - TY - JOUR AU - Hale, G. AU - Rebello, P. AU - Brettman, L. R. PY - 2004 DA - 2004// TI - Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration JO - Blood VL - 104 ID - Hale2004 ER - TY - JOUR AU - Alinari, L. AU - Geskin, L. AU - Grady, T. PY - 2008 DA - 2008// TI - Subcutaneous alemtuzumab for Sezary syndrome in the very elderly JO - Leuk Res VL - 32 ID - Alinari2008 ER - TY - JOUR AU - Zinzani, P. L. AU - Alinari, L. AU - Tani, M. PY - 2005 DA - 2005// TI - Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma JO - Haematologica VL - 90 ID - Zinzani2005 ER - TY - JOUR AU - Bernengo, M. G. AU - Quaglino, P. AU - Comessatti, A. PY - 2007 DA - 2007// TI - Low-dose of intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients JO - Haematologica VL - 92 ID - Bernengo2007 ER - TY - JOUR AU - Knox, S. J. AU - Levy, R. AU - Hodgkinson, S. PY - 1991 DA - 1991// TI - Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides JO - Blood VL - 77 ID - Knox1991 ER - TY - JOUR AU - Knox, S. AU - Hoppe, R. T. AU - Maloney, D. PY - 1996 DA - 1996// TI - Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody JO - Blood VL - 87 ID - Knox1996 ER - TY - JOUR AU - Kim, Y. AU - Duvic, M. AU - Obitz, E. PY - 2007 DA - 2007// TI - Clinical efficacy of zanolimumab (HuMax-CD4): two phase II studies in refractory cutaneous T-cell lymphoma JO - Blood VL - 109 ID - Kim2007 ER - TY - JOUR AU - Wahl, A. F. AU - Klussman, K. AU - Thompson, J. D. PY - 2002 DA - 2002// TI - The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease JO - Cancer Res VL - 62 ID - Wahl2002 ER - TY - JOUR AU - Bartlett, N. L. AU - Younes, A. AU - Carabasi, M. H. PY - 2008 DA - 2008// TI - A phase I multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies JO - Blood VL - 111 ID - Bartlett2008 ER - TY - JOUR AU - Ansell, S. M. AU - Horwitz, S. M. AU - Engert, A. PY - 2007 DA - 2007// TI - Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma JO - J Clin Oncol VL - 25 ID - Ansell2007 ER - TY - JOUR AU - Younes, A. PY - 2011 DA - 2011// TI - Beyond chemotherapy: new agents for targeted treatment of lymphoma JO - Nat Rev Clin Oncol VL - 8 ID - Younes2011 ER - TY - JOUR AU - Duvic, M. AU - Reddy, S. AU - Pinter Brown, L. PY - 2009 DA - 2009// TI - A phase II study of SGN- 30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders JO - Clin Cancer Res VL - 15 ID - Duvic2009 ER - TY - JOUR AU - Younes, A. AU - Bartlett, N. L. AU - Leonard, J. P. PY - 2010 DA - 2010// TI - Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas JO - N Engl J Med VL - 363 ID - Younes2010 ER - TY - JOUR AU - Bartlett, N. L. AU - Forero-Torres, A. AU - Rosenblatt, J. PY - 2009 DA - 2009// TI - Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL) JO - ASCO Meeting Abstracts VL - 27 ID - Bartlett2009 ER - TY - JOUR AU - Chen, R. W. AU - Gopal, A. K. AU - Smith, S. E. PY - 2011 DA - 2011// TI - Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) JO - ASCO Meeting Abstracts VL - 29 ID - Chen2011 ER - TY - JOUR AU - Pro, B. AU - Advani, R. AU - Brice, P. PY - 2011 DA - 2011// TI - Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) JO - ASCO Meeting Abstracts VL - 29 ID - Pro2011 ER - TY - CHAP AU - Dummer, R. AU - Whittaker, S. AU - Hasan, B. PY - 2010 DA - 2010// TI - EORTC 21012: Phase II multicenter study of CaelyxTM monotherapy in patients with advanced mycosis fungoides stage IIb, IVa and IVb with or without previous chemotherapy BT - Blood ID - Dummer2010 ER - TY - JOUR AU - Querfeld, C. AU - Rizvi, M. A. AU - Kuzel, T. M. PY - 2006 DA - 2006// TI - The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway JO - J Invest Dermatol VL - 126 ID - Querfeld2006 ER - TY - JOUR AU - Carducci, M. A. AU - Musib, L. AU - Kies, M. S. PY - 2006 DA - 2006// TI - Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinse C beta inhibitor, in patients with advanced cancer JO - J Clin Oncol VL - 24 ID - Carducci2006 ER - TY - JOUR AU - Querfeld, C. AU - Kuzel, T. M. AU - Kim, Y. H. PY - 2011 DA - 2011// TI - Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma JO - Leuk Lymphoma VL - 52 ID - Querfeld2011 ER - TY - JOUR AU - Brody, J. AU - Ai, W. AU - Czerwinski, D. PY - 2010 DA - 2010// TI - In situ vaccination of a TLR9 agonist induces systemic lymphoma regression JO - J Clin Oncol VL - 28 ID - Brody2010 ER - TY - CHAP AU - Kim, Y. H. AU - Gratzinger, D. AU - Harrison, C. PY - 2011 DA - 2011// TI - In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase I/II study BT - Blood ID - Kim2011 ER - TY - JOUR AU - Querfeld, C. AU - Kuzel, T. M. AU - Guitart, J. PY - 2006 DA - 2006// TI - Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma JO - Haematol Rep VL - 2 ID - Querfeld2006 ER -